Highest-materiality recent filing
Trevi Therapeutics Q2 2026 net loss $17.8M; cash $318.9M; Phase 3 OCEAN-1 initiated
Net loss of $17.8M in Q2 2026 vs $12.3M in Q2 2025; R&D expenses $15.2M (up from $9.4M).
Elected Michael Heffernan as Class I director for a term expiring at the 2029 annual meeting.
Trevi Therapeutics reports Q1 net loss $13.2M; cash runway extended to 2030 after $162M offering
Net loss of $13.2M in Q1 2026 vs $10.3M YoY; R&D expenses $9.9M, G&A $5.0M.
Trevi Therapeutics prices $150M stock offering; provides Haduvio trial updates
Offering of 11.6M shares at $13.00/sh; net proceeds ~$141.1M (or ~$162.4M if option exercised).
Trevi gains FDA alignment on Phase 3 IPF-cough program; cash $188.3M
FDA alignment on Phase 3 program for IPF-related chronic cough; first Phase 3 trial to start Q2 2026.
End-of-Phase 2 FDA meeting: overall alignment on IPF-related chronic cough development program including two pivotal Phase 3 trials and Phase 1 studies for NDA support.
Trevi Therapeutics appoints David Hastings as CFO effective January 6, 2026
David Hastings previously served as CFO of Arbutus Biopharma (June 2018–March 2025).
Trevi Q3 net loss $11.8M; cash $194.9M funds operations into 2028
Net loss of $11.8M for Q3 2025 vs. $13.2M in Q3 2024; R&D spend down to $10.1M.
CFO Lisa Delfini will resign effective August 22, 2025; departure is not due to any disagreement with the company.
Trevi Q2 net loss $12.3M; positive Phase 2b CORAL results for Haduvio in IPF cough
Haduvio met primary endpoint with 60.2% cough reduction (108 mg BID) vs 16.9% placebo (p<0.0001).
Trevi shareholders approve 6M share increase for 2019 Stock Incentive Plan
Stockholders voted to increase authorized shares under the 2019 Plan by 6,000,000 shares.
Trevi Therapeutics prices $100M common stock offering at $5.75 per share
Offering of 17.4M shares at $5.75/share; net proceeds ~$93.7M (~$107.8M if underwriters' option fully exercised).
Trevi Therapeutics reports positive Phase 2b topline results for Haduvio in IPF chronic cough
Primary endpoint met: 60.2% reduction in 24-hour cough frequency at 108 mg BID (p<0.0001) vs 16.9% placebo.
Trevi Therapeutics terminates ATM prospectus; past sales $14.6M gross
On June 2, 2025, Trevi terminated the August 15, 2023 ATM prospectus with Leerink Partners.
Trevi Therapeutics Q1 net loss $10.3M; positive RIVER trial results; CORAL data expected Q2 2025
Net loss of $10.3M ($10.9M YoY); R&D expenses $7.8M, G&A $3.7M.
Announced positive topline data from Phase 2a RIVER trial in refractory chronic cough, meeting primary endpoint with 57% placebo-adjusted reduction in 24-hour cough frequency.
Trevi's Haduvio meets Phase 2a RIVER primary endpoint; 57% placebo-adjusted cough reduction
Primary endpoint: 67% reduction from baseline in 24-hour cough frequency; 57% placebo-adjusted (p<0.0001).
Trevi Therapeutics reports $107.6M cash; Phase 2a RIVER completed enrollment; CORAL 80% enrolled
Cash, cash equivalents, and marketable securities estimated at $107.6M as of Dec 31, 2024; runway into H2 2026.
Trevi prices $50M underwritten offering of 12.5M shares at $4.00 per share
Offering of 12.5M shares at $4.00/share; net proceeds ~$46.7M after underwriting discounts and expenses.
SSRE analysis on highest 108mg BID dose after 80 patients completed 6 weeks recommended continuing as planned; no sample size increase or futility.
Primary endpoint: mean Emax for 'Drug Liking' for oral nalbuphine 81mg was 71.2 vs IV butorphanol 6mg (82.3), p<0.0001.
Trevi Therapeutics reports Q3 net loss of $13.2M; completes Phase 2a RIVER enrollment
Net loss of $13.2M for Q3 2024 vs $7.7M loss in Q3 2023; R&D expenses rose to $11.2M from $6.3M.
Trevi Therapeutics completes enrollment in Phase 2a RIVER trial of Haduvio; topline data due Q1 2025
Trevi Therapeutics (Nasdaq: TRVI) completed enrollment in its Phase 2a RIVER trial of Haduvio (oral nalbuphine ER).
Phase 2b CORAL trial for chronic cough in IPF enrolled 50% of target (N=160); SSRE expected December 2024.
Trevi Therapeutics names James Cassella Chief Development Officer; CMO David Clark departs
James Cassella appointed CDO effective Sept 30, 2024; he resigned from the Board on that date.
Trevi Therapeutics Q2 net loss $12.4M; RIVER trial ~80% enrolled, topline Q4 2024
Q2 2024 net loss of $12.4M vs $7.1M in Q2 2023; R&D expenses $10.0M, up from $5.8M.
Trevi Therapeutics annual meeting results: all director nominees elected, auditor ratified
Dominick Colangelo re-elected as Class II director with 47.1M votes for (99.8% of votes cast).
Trevi Therapeutics Q1 2024 net loss $10.9M; cash $72.8M; clinical trials on track
Net loss of $10.9M vs $6.4M in Q1 2023; R&D expense rose to $8.8M from $5.0M.
Trevi Therapeutics reports FY2023 net loss $29.1M; cash $83M; trial timelines reaffirmed
Net loss Q4 2023 $7.8M vs $5.5M in Q4 2022; FY2023 net loss $29.1M vs $29.2M in FY2022.
Trevi Therapeutics Q3 2023 net loss $7.7M; initiates Phase 2a RIVER trial for Haduvio in RCC
Net loss $7.7M in Q3 2023 vs $8.3M in Q3 2022; cash, equivalents $88.9M.
Trevi Therapeutics Q2 net loss $7.1M; cash $94.2M; three chronic cough trials on track for H2 2023
Net loss of $7.1M in Q2 2023 vs. $8.1M in Q2 2022; R&D expenses rose to $5.8M.
Stockholders approve certificate amendment to extend exculpation to senior officers
Amendment to restated certificate of incorporation approved to include certain senior corporate officers in director exculpation provision.
Trevi Therapeutics reports Q1 net loss of $6.4M; plans three chronic cough trials in H2 2023
Net loss of $6.4M in Q1 2023 vs. $7.3M in Q1 2022; cash and equivalents $111.3M.
Trevi Therapeutics amends bylaws to update proxy rules and meeting procedures
Eliminated requirement for stockholder list to be available at meeting.
Trevi Therapeutics reports Q4 2022 net loss $5.5M; cash $120.5M into 2026
Net loss Q4 2022: $5.5M ($0.05 per share) vs $8.5M loss same period 2021. Full-year loss $29.2M vs $33.9M.
Trevi Therapeutics reports Q3 2022 net loss of $8.3M; cash at $126M
Net loss of $8.3M in Q3 2022 vs. $7.3M in Q3 2021; R&D expenses rose to $5.8M.
Trevi Therapeutics prices $55M public offering of common stock and pre-funded warrants
Offering of 14,252,670 shares at $1.93/share and pre-funded warrants to buy 14,247,330 shares at $1.929 each.
Trevi reports positive Phase 2 CANAL data: Haduvio reduces daytime cough 75% vs 23% placebo
Primary endpoint met: placebo-adjusted daytime cough frequency reduction 52.5% (p<0.0001).
Q2 2022 net loss of $8.1M ($9.8M in Q2 2021); cash and securities $78.9M.
Trevi Therapeutics reports positive Phase 2b/3 PRISM trial for Haduvio in prurigo nodularis
Primary endpoint met: 25% of Haduvio subjects achieved 4-point WI-NRS reduction vs 14% placebo (p=0.0157).
Trevi Therapeutics shareholders elect Good and VanLent, ratify EY as auditor
Jennifer Good received 21,768,228 votes for and 178,450 withheld; broker non-votes 9,566,404.
Trevi Therapeutics expands at-the-market equity facility by $50M to $62M total
Amended Sales Agreement with SVB Securities to increase max aggregate offering from $12M to $62M, adding $50M in capacity.
Q1 2022 net loss $7.3M vs $8.4M prior year; R&D expenses $4.6M down from $5.6M.
Trevi Therapeutics raises ~$55M in private placement; amends SVB loan facility
Gross proceeds ~$55M from sale of 4.58M shares at $1.90/share and pre-funded warrants for 24.38M shares at $1.899.
Trevi: Phase 2 CANAL interim p<0.0001 (52% cough reduction); PRISM enrollment done
Phase 2 CANAL interim analysis: 52% placebo-adjusted reduction in daytime cough events (p<0.0001); enrollment ended early; full data Q3 2022.
Trevi Therapeutics regains Nasdaq minimum bid price compliance
Received Nasdaq deficiency letter on Jan 10, 2022 for bid price below $1 for 30 consecutive days.
Interim analysis (N=26) showed 52% placebo-adjusted reduction in daytime cough frequency (p<0.0001); 100% probability of success.
PRISM trial enrolled ~360 subjects with severe pruritus and prurigo nodularis.
Received deficiency letter from Nasdaq on Jan 10, 2022; bid price closed below $1.00 for 30 consecutive business days.
Trevi announces interim analysis for Phase 2 CANAL trial in Q1 2022, ends PRISM enrollment Jan 31
Phase 2 CANAL trial of Haduvio for chronic cough in IPF: interim statistical update planned Q1 2022 based on conditional power.
David Clark, MBChB, MRCP, had stepped down as the Company’s Chief Medical Officer, effective as of September 27, 2024.
Dr. Cassella resigned from his position as a member of the Board of Directors of the Company, effective as of September 30, 2024.
announced that James Cassella, Ph.D., had agreed to join the Company as its Chief Development Officer.
On August 9, 2021, Trevi Therapeutics, Inc. (the “Company”) announced the hiring of Lisa Delfini, who will serve as the Company’s Chief Financial Officer and principal financial officer upon her start date of August 9, 2021.
Max materiality 0.85 · Median 0.65 · Most common event other_material